Trial Information

Additional Circulating Markers of Angiogenesis and Disease in Mesothelioma Patients Treated on CALGB 30107

OBJECTIVES:

- Determine if elevated levels of thrombospondin I serum levels, vascular endothelial
growth factor receptor I, fibroblast growth factor, transforming growth factor, and
mesothelin portend a poor prognosis in patients with unresectable malignant
mesothelioma treated with vatalanib on protocol CALGB-30107.

- Determine if elevated levels of thrombospondin I serum levels, vascular endothelial
growth factor receptor I, fibroblast growth factor, transforming growth factor, and
mesothelin correlate with response or stable disease in these patients.

OUTLINE: Serum samples previously obtained from patients on protocol CALGB-30107 are tested
for levels of thrombospondin I serum, vascular endothelial growth factor receptor I,
fibroblast growth factor, transforming growth factor, and mesothelin using enzyme-linked
immunosorbent assays (ELISA).

PROJECTED ACCRUAL: A total of 47 specimens will be accrued for this study.